187 related articles for article (PubMed ID: 32376439)
1. High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats.
Al-Ali AAA; Sandra L; Versweyveld D; Pijpers I; Dillen L; Vermeulen A; Snoeys J; Holm R; Nielsen CU
Int J Pharm; 2020 Jun; 583():119399. PubMed ID: 32376439
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Lee CK; Ki SH; Choi JS
Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
[TBL] [Abstract][Full Text] [Related]
3. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
4. Increased bioavailability of a P-gp substrate: Co-release of etoposide and zosuquidar from amorphous solid dispersions.
Nielsen RB; Larsen BS; Holm R; Pijpers I; Snoeys J; Nielsen UG; Tho I; Nielsen CU
Int J Pharm; 2023 Jul; 642():123094. PubMed ID: 37263451
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration.
Matzneller P; Kussmann M; Eberl S; Maier-Salamon A; Jäger W; Bauer M; Langer O; Zeitlinger M; Poeppl W
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):599-606. PubMed ID: 29616423
[TBL] [Abstract][Full Text] [Related]
6. Effect of hydroxyzine on the transport of etoposide in rat small intestine.
Kan WM; Liu YT; Hsiao CL; Shieh CY; Kuo JH; Huang JD; Su SF
Anticancer Drugs; 2001 Mar; 12(3):267-73. PubMed ID: 11290874
[TBL] [Abstract][Full Text] [Related]
7. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
[TBL] [Abstract][Full Text] [Related]
8. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.
Zhang H; Yao M; Morrison RA; Chong S
Arch Pharm Res; 2003 Sep; 26(9):768-72. PubMed ID: 14560928
[TBL] [Abstract][Full Text] [Related]
9. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
10. Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations.
Fatma S; Talegaonkar S; Iqbal Z; Panda AK; Negi LM; Goswami DG; Tariq M
Drug Deliv; 2016; 23(2):500-11. PubMed ID: 24937381
[TBL] [Abstract][Full Text] [Related]
11. Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats.
Al-Ali AAA; Quach JRC; Bundgaard C; Steffansen B; Holm R; Nielsen CU
Int J Pharm; 2018 May; 543(1-2):352-360. PubMed ID: 29635055
[TBL] [Abstract][Full Text] [Related]
12. Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats.
Piao YJ; Li X; Choi JS
Eur J Drug Metab Pharmacokinet; 2008; 33(3):159-64. PubMed ID: 19007041
[TBL] [Abstract][Full Text] [Related]
13. Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition.
Zhao G; Huang J; Xue K; Si L; Li G
Eur J Pharm Sci; 2013 Nov; 50(3-4):429-39. PubMed ID: 23981337
[TBL] [Abstract][Full Text] [Related]
14. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
15. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
[TBL] [Abstract][Full Text] [Related]
16. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates.
Kwon H; Lionberger RA; Yu LX
Mol Pharm; 2004; 1(6):455-65. PubMed ID: 16028357
[TBL] [Abstract][Full Text] [Related]
17. Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs.
Khalid N; Sarfraz M; Arafat M; Akhtar M; Löbenberg R; Ur Rehman N
J Pharm Pharm Sci; 2018; 21(1):398-408. PubMed ID: 30365396
[TBL] [Abstract][Full Text] [Related]
18. Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and
Nielsen RB; Holm R; Pijpers I; Snoeys J; Nielsen UG; Nielsen CU
Int J Pharm X; 2021 Dec; 3():100089. PubMed ID: 34977557
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
Yang S; Gursoy RN; Lambert G; Benita S
Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
[TBL] [Abstract][Full Text] [Related]
20. Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation.
Akhtar N; Talegaonkar S; Khar RK; Jaggi M
J Biomed Nanotechnol; 2013 Jul; 9(7):1216-29. PubMed ID: 23909136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
